AR091739A1 - Composiciones y metodos para reducir el riesgo cardiometabolico - Google Patents

Composiciones y metodos para reducir el riesgo cardiometabolico

Info

Publication number
AR091739A1
AR091739A1 ARP130102472A AR091739A1 AR 091739 A1 AR091739 A1 AR 091739A1 AR P130102472 A ARP130102472 A AR P130102472A AR 091739 A1 AR091739 A1 AR 091739A1
Authority
AR
Argentina
Prior art keywords
compositions
methods
cardiometabolic risk
reduce
reduce cardiometabolic
Prior art date
Application number
Other languages
English (en)
Inventor
S Fineman Mark
D Baron Alain
R A Beeley Nigel
Original Assignee
Elcelyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/547,022 external-priority patent/US8796338B2/en
Priority claimed from US13/734,966 external-priority patent/US9211263B2/en
Application filed by Elcelyx Therapeutics Inc filed Critical Elcelyx Therapeutics Inc
Publication of AR091739A1 publication Critical patent/AR091739A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones y métodos que comprenden por lo menos un compuesto biguanida y por lo menos una estatina en combinación con por lo menos un agente activo adicional en combinaciones de dosis fijas para reducir el riesgo cardiometabólico, y para el tratamiento de la enfermedad cardiovascular, en donde el compuesto biguanida está formulado para una liberación retardada.
ARP130102472 2012-07-11 2013-07-11 Composiciones y metodos para reducir el riesgo cardiometabolico AR091739A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/547,022 US8796338B2 (en) 2011-01-07 2012-07-11 Biguanide compositions and methods of treating metabolic disorders
US13/734,966 US9211263B2 (en) 2012-01-06 2013-01-05 Compositions and methods of treating metabolic disorders

Publications (1)

Publication Number Publication Date
AR091739A1 true AR091739A1 (es) 2015-02-25

Family

ID=48833086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102472 AR091739A1 (es) 2012-07-11 2013-07-11 Composiciones y metodos para reducir el riesgo cardiometabolico

Country Status (9)

Country Link
EP (1) EP2872127A1 (es)
JP (2) JP2015522080A (es)
CN (1) CN104780915A (es)
AR (1) AR091739A1 (es)
AU (1) AU2013290100A1 (es)
CA (1) CA2878625A1 (es)
HK (1) HK1210825A1 (es)
IL (1) IL236647A0 (es)
WO (1) WO2014011926A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104906582A (zh) 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SI2986304T1 (sl) 2013-04-18 2022-04-29 Boehringer Ingelheim International Gmbh Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
WO2019128991A1 (en) * 2017-12-26 2019-07-04 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2704146B1 (fr) 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
HUP0000838A3 (en) 1997-04-15 2001-04-28 Csir Extract containing steroid-glucosid, process for its isolation and synthesis, pharmaceutical composition containing it having appetite suppressant activity
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US6180365B1 (en) 1998-11-06 2001-01-30 Smithkline Beecham Corporation Polynucleotide encoding a Mouse 7-transmembrane GPR43 receptor
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
IL132313A0 (en) 1999-10-11 2001-03-19 Yeda Res & Dev Leptin assay
US20030113810A1 (en) 2000-02-18 2003-06-19 Alan Wise Novel assay
US20110217394A1 (en) 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
JP4360915B2 (ja) 2002-01-07 2009-11-11 ユーロスクリーン・ソシエテ・アノニム Ｇタンパク質共役受容体ｇｐｒ４３のリガンドおよびその使用
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20060019346A1 (en) 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
EP1551403B1 (en) 2002-10-10 2009-04-29 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
WO2004038421A2 (en) 2002-10-25 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
AU2003273994A1 (en) 2002-10-25 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
CN1413582A (zh) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
JP4654038B2 (ja) 2002-12-18 2011-03-16 ジボダン エス エー キメラアルファｑ−ガストデューシンｇタンパク質
EP1597588A1 (en) 2003-02-17 2005-11-23 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40)
DE10308504A1 (de) 2003-02-26 2004-09-09 Basf Ag Enzymatische Herstellung von (Meth)acrylsäureestern
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
AU2004260636A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
WO2005009351A2 (en) 2003-07-17 2005-02-03 Santé International, Inc. Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics
AU2003269484A1 (en) * 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
US20070093545A1 (en) 2003-11-21 2007-04-26 Arena Pharmaceuticals, Inc. 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
WO2005102311A1 (en) 2004-04-20 2005-11-03 Deutsches Institut für Ernährungsforschung Agonists of a bitter taste receptor and uses thereof
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
US20060024335A1 (en) 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
CA2580130A1 (en) 2004-09-22 2006-04-06 Arena Pharmaceuticals, Inc. Gpr43 and modulators thereof for the treatment of metabolic-related disorders
US20080021069A1 (en) 2004-10-08 2008-01-24 Takeda Pharmaceutical Company Limited Receptor Function Regulating Agent
CA2584224A1 (en) 2004-11-03 2006-05-18 Arena Pharmaceuticals, Inc. Gpr41 and modulators thereof for the treatment of insulin-related disorders
US7829299B2 (en) 2004-11-18 2010-11-09 Deutsches Institut fur Ernahrungforschung Potsdam-Rehbrucke Stiftung des Offentlichen Rechts Agonists of bitter taste receptors and uses thereof
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US20080090865A1 (en) 2005-01-28 2008-04-17 Min Ge Antidiabetic Bicyclic Compounds
CA2593858A1 (en) 2005-01-31 2006-08-10 Min Ge Antidiabetic bicyclic compounds
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
WO2006102653A2 (en) 2005-03-24 2006-09-28 Irm Llc Methods and compositions for treating insulin resistance and obesity-induced diseases
EP1878734A4 (en) 2005-04-28 2010-02-17 Ajinomoto Kk NEW COMPOUND LACTAME
EP1899304A1 (en) 2005-05-23 2008-03-19 Arena Pharmaceuticals, Inc. 5-amino-1h-pyrazole-3-carboxylic acid derivatives as agonists for the g-protein coupled receptor (gpcr) rup38 for the treatment of metabolic-related disorders thereof
US20060269617A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Supplement compositions and method of use for enhancement of insulin sensitivity
AU2006262399A1 (en) 2005-06-22 2007-01-04 Senomyx, Inc. Identification of human T2R recepors that are activated by bitter molecules in coffee (chlorogenic lactones) and related assays for identifying human bitter taste modulators
EP1907422A1 (en) 2005-07-28 2008-04-09 Nestec S.A. Fat taste receptors and their methods of use
WO2007013689A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
EP1924709A1 (en) 2005-08-10 2008-05-28 Arena Pharmaceuticals, Inc. Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist
JP4932724B2 (ja) 2005-09-02 2012-05-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｇｐｒ１２０とホスホリパーゼとを用いる疾患に有用な物質のスクリーニング方法
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
US20070104805A1 (en) 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
JP2007215162A (ja) 2006-01-11 2007-08-23 Canon Inc 情報処理装置及びその制御方法、プログラム、記憶媒体
US20070207227A1 (en) 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
MX2008012814A (es) 2006-04-06 2008-10-17 Prosidion Ltd Agonistas del receptor acoplado a la proteina g heterociclicos.
WO2007116404A2 (en) 2006-04-10 2007-10-18 Bar-Ilan University Cucurbitacin glucosides and use thereof in treating cancer
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
EP2369341A3 (en) 2006-04-11 2012-01-04 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
JP5271895B2 (ja) 2006-05-15 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション 抗糖尿病性の二環式化合物
WO2007134613A1 (en) 2006-05-24 2007-11-29 Rheoscience A/S Modulation of gpr120 activity in adipocytes/fat tissue
RS52307B (en) 2006-06-27 2012-12-31 Takeda Pharmaceutical Company Limited CONDENSED CYCLIC UNITS
CA2551706A1 (en) 2006-06-27 2007-12-27 Innovative Life Sciences Corporation Herbal product comprising cinnamon and bitter melon
CN100596277C (zh) 2006-07-10 2010-03-31 博仲盛景医药技术（北京）有限公司 一种促进肠胃蠕动的药物组合物
JP2009543805A (ja) 2006-07-13 2009-12-10 スミスクライン ビーチャム コーポレーション インドリン誘導体及びｇｐｒ１１９作動物質
CA2660464A1 (en) 2006-08-17 2008-02-21 Unilever Plc Processes for production of hoodia plant extracts containing steroidal glycosides
CA2661593A1 (en) 2006-08-24 2008-02-28 Unilever Plc Process for preparing a composition comprising steroidal glycosides
JP2010501630A (ja) 2006-08-30 2010-01-21 ビオヴィトルム・アクチボラゲット（プブリクト） Ｇｐｒ１１９関連障害を治療するためのピリミジン化合物
WO2008030429A2 (en) 2006-09-05 2008-03-13 Senomyx, Inc. Novel haplotype of human t2r receptor ht2r50 and its use in assays for identifying human bitter taste modulators
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
WO2008063321A2 (en) 2006-10-13 2008-05-29 Janssen Pharmaceutica N.V. Gpr81-ligand complexes and their preparation and use
JP2010508268A (ja) 2006-10-31 2010-03-18 メルク エンド カムパニー インコーポレーテッド 抗糖尿病二環式化合物
WO2008054674A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
BRMU8602999U (pt) * 2006-11-16 2008-07-08 Walter Junior Santos medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares
WO2008058355A2 (en) * 2006-11-16 2008-05-22 Walter Santos Junior Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
CN101190179B (zh) * 2006-11-20 2010-05-12 北京利龄恒泰药业有限公司 一种治疗糖尿病的肠溶药物组合物及其制备方法
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
AU2007326395B2 (en) 2006-12-01 2012-10-11 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
US8058312B2 (en) * 2007-01-29 2011-11-15 Hanall Biopharma Co., Ltd. N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
CN101663298A (zh) 2007-02-22 2010-03-03 Irm责任有限公司 作为g蛋白偶联受体调节剂的噻唑衍生物
AU2008222812B2 (en) 2007-03-08 2012-03-22 Irm Llc Compounds and compositions as modulators of GPR119 activity
EP1975612A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP1975611A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
EP2148679A1 (en) 2007-04-20 2010-02-03 Schering Corporation Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof
JP2010524941A (ja) 2007-04-20 2010-07-22 シェーリング コーポレイション ピリミジノン誘導体およびそれらの使用方法
CA2684633A1 (en) 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
JP5420400B2 (ja) 2007-04-26 2014-02-19 国立大学法人京都大学 Ｇタンパク質共役型レセプター作動剤
WO2008137435A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
EP2152707B1 (en) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
US8309534B2 (en) 2007-05-15 2012-11-13 Medical College Of Georgia Research Institute, Inc. Compositions comprising a GPR109 ligand for treating disorders of the digestive tract and/or cancer
KR20100051814A (ko) 2007-07-17 2010-05-18 브리스톨-마이어스 스큅 컴퍼니 Ｇｐｒ１１９ ｇ 단백질-커플링된 수용체의 조절 방법 및 선택된 화합물
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US20090042813A1 (en) 2007-08-10 2009-02-12 Sergey Michailovich Melnikov Hoodia extract oil compositions comprising medium chain triglycerides
WO2009033078A2 (en) 2007-09-05 2009-03-12 Raif Tawakol Compositions and methods for controlling cholesterol levels
US20100286112A1 (en) 2007-09-10 2010-11-11 Oscar Barba Compounds for the treatment of metabolic disorders
WO2009038204A1 (ja) 2007-09-17 2009-03-26 Pharma Frontier Co., Ltd. 新規長鎖脂肪酸誘導体化合物及びそれら化合物を有効成分とするｇタンパク質共役型レセプター作動剤
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 ｇｒｐ４０ 조절제
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
JP2011016722A (ja) 2007-10-23 2011-01-27 Astellas Pharma Inc チアゾリジンジオン化合物
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
US20100316736A1 (en) 2007-10-24 2010-12-16 Desert Labs Agriculture Cooperative Association Ltd. Appetite suppressant
AU2008319418B2 (en) 2007-10-29 2013-08-15 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN101918014B (zh) 2008-01-29 2012-06-20 中森制药株式会社 医药组合物
AU2009217359B2 (en) 2008-02-22 2011-09-01 Irm Llc Compounds and compositions as modulators of GPR119 activity
US20110172244A1 (en) 2008-02-22 2011-07-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
CA2716330A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009106565A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CL2009000782A1 (es) 2008-03-31 2010-04-30 Metabolex Inc Metodo que comprende un compuesto derivado de oximetilen-arilo sustituido, inhibidores de dpp-iv; y su uso en el tratamiento de la diabetes y disminucion de trigliceridos, entre otras enfermedades.
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
CN102056900A (zh) 2008-04-07 2011-05-11 Irm责任有限公司 作为gpr119活性调节剂的化合物和组合物
WO2009125804A1 (ja) 2008-04-09 2009-10-15 武田薬品工業株式会社 スクリーニング方法
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
US9844224B2 (en) 2008-05-23 2017-12-19 Givaudan Sa Bitter alkaloid containing consumables comprising bitter blockers
WO2009151542A2 (en) 2008-05-27 2009-12-17 Duke University Nicotinic acid receptor ligands
CN101695575A (zh) * 2008-05-29 2010-04-21 北京奥萨医药研究中心有限公司 含有他汀类降脂药物、双胍类降糖药物和烟酸的药物组合物
US20110065739A1 (en) 2008-06-02 2011-03-17 Makoto Ishikawa Novel isoxazole drivative
WO2009150144A1 (en) 2008-06-10 2009-12-17 Inovacia Ab New gpr119modulators
US8546085B2 (en) 2008-06-13 2013-10-01 Givaudan Sa Methods of identifying modulators of the bitter taste receptor TAS2R44
BRPI0914891A2 (pt) 2008-06-20 2015-11-24 Metabolex Inc agonistas de aril gpr119 e usos dos mesmos
GB0812031D0 (en) 2008-07-01 2008-08-06 7Tm Pharma As Thiazole derivatives
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
CN102137844B (zh) 2008-07-11 2013-05-22 Irm责任有限公司 作为gpr119活性调控剂的化合物和组合物
JP2011528365A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション Ｇｐｒ１１９モジュレーターとしての二環式ヘテロ環誘導体およびそれらの使用方法
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
CN105152919A (zh) 2008-07-28 2015-12-16 赛丹思科大学 用于治疗代谢疾病的化合物
EP2311822A4 (en) 2008-08-01 2011-08-31 Nippon Chemiphar Co GPR119 AGONIST
WO2010022529A1 (en) 2008-08-29 2010-03-04 Givaudan Sa Methods to identify modulators
ES2550077T3 (es) 2008-08-29 2015-11-04 Suntory Holdings Limited Nuevo tetrámero de galato de epigalocatequina y mejorador de la función del endotelio vascular que comprende el mismo
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
MX2011004125A (es) 2008-10-21 2011-05-19 Metabolex Inc Agonistas del receptor gpr120 de arilo y usos de los mismos.
WO2010060198A1 (en) 2008-11-26 2010-06-03 West Central Envirotech Inc. Composition and method for controlling insects
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010074271A1 (ja) 2008-12-26 2010-07-01 武田薬品工業株式会社 糖尿病治療剤
CN102272129B (zh) 2009-01-03 2014-10-08 静冈县公立大学法人 硫酸化c-糖苷及其分离方法以及合成方法
JPWO2010084944A1 (ja) 2009-01-22 2012-07-19 田辺三菱製薬株式会社 新規ピロロ［２，３−ｄ］ピリミジン化合物
CA2749663A1 (en) 2009-01-23 2010-07-29 Hubert B. Josien Pentafluorosulpholane-containing antidiabetic compounds
US20110312967A1 (en) 2009-01-23 2011-12-22 Schering Corporation Bridged and fused antidiabetic compounds
CA2749930A1 (en) 2009-01-23 2010-07-29 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
TW201040186A (en) 2009-02-05 2010-11-16 Schering Corp Phthalazine-containing antidiabetic compounds
US8410089B2 (en) 2009-02-18 2013-04-02 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
CA2754523A1 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
JP2012136438A (ja) 2009-04-22 2012-07-19 Astellas Pharma Inc テトラゾール化合物
CN102421739A (zh) 2009-04-22 2012-04-18 安斯泰来制药株式会社 羧酸化合物
JP2012136439A (ja) 2009-04-24 2012-07-19 Nippon Chemiphar Co Ltd ジアザスピロアルカン誘導体
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
JP2012526097A (ja) 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
AU2010255422B2 (en) 2009-06-05 2014-04-10 Pfizer Inc. 1- ( piperidin-4-yl) -pyrazole derivatives as GPR 119 modulators
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
AR077638A1 (es) 2009-07-15 2011-09-14 Lilly Co Eli Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
WO2011012298A1 (en) 2009-07-28 2011-02-03 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
EP2474540A4 (en) 2009-08-31 2013-03-13 Nippon Chemiphar Co GPR119 AGONIST
MY158504A (en) 2009-09-01 2016-10-14 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
CA2772188A1 (en) 2009-09-23 2011-03-31 Pfizer Inc. Gpr 119 modulators
US20110082156A1 (en) 2009-10-05 2011-04-07 Milne Jill C Fatty acid acipimox derivatives and their uses
US20110082202A1 (en) 2009-10-05 2011-04-07 Milne Jill C Fatty acid acifran derivatives and their uses
EP2486005B1 (en) 2009-10-06 2014-06-18 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
CN102686579A (zh) 2009-10-09 2012-09-19 Irm责任有限公司 作为gpr119活性调节剂的化合物和组合物
WO2011051966A2 (en) * 2009-10-12 2011-05-05 Ipca Laboratories Limited Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
WO2011050163A1 (en) 2009-10-21 2011-04-28 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
EP2493307B1 (en) 2009-10-29 2016-04-27 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
CA2779398A1 (en) 2009-10-30 2011-05-05 Mochida Phamaceutical Co., Ltd. Novel 3-hydroxy-5-arylisoxazole derivative
JPWO2011055770A1 (ja) 2009-11-06 2013-03-28 武田薬品工業株式会社 縮合複素環化合物
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia
WO2011061679A1 (en) 2009-11-23 2011-05-26 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
RU2012127779A (ru) 2009-12-04 2014-01-20 Колгейт-Палмолив Компани КОМПОЗИЦИЯ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА, СОДЕРЖАЩАЯ ЭКСТРАКТЫ ИЗ Garcinia mangostana L., И СВЯЗАННЫЕ С НЕЙ СПОСОБЫ
EP2332427A1 (en) 2009-12-07 2011-06-15 Nestec S.A. low caloric fat replacers
WO2011072132A1 (en) 2009-12-09 2011-06-16 The Regents Of The University Of California Methods of treating inflammatory conditions
RS56751B1 (sr) 2009-12-18 2018-04-30 Ogeda Sa Derivati pirolidin karboksilne kiseline kao agonisti g-protein spojenog receptora 43 (gpr43), farmaceutska kompozicija i postupci za upotrebu u lečenju metaboličkih poremećaja
JP2013047188A (ja) 2009-12-24 2013-03-07 Nippon Chemiphar Co Ltd Ｇｐｒ１１９作動薬
AU2010336225A1 (en) 2009-12-25 2012-08-16 Mochida Pharmaceutical Co.,Ltd. Novel 3-hydroxy-5-arylisothiazole derivative
EP2345646A1 (en) 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
WO2011092284A1 (en) 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
CN101785763B (zh) * 2010-02-04 2011-11-23 贵州天安药业股份有限公司 一种盐酸二甲双胍肠溶缓释片及其制备方法
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102918027A (zh) 2010-04-06 2013-02-06 艾尼纳制药公司 Gpr119受体调节剂和对与所述受体有关的障碍的治疗
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
BR112012028445A2 (pt) 2010-05-06 2016-07-19 Bristol Myers Squibb Co compostos de heteroarila bicíclica como moduladores de gpr119
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
WO2011138427A2 (en) 2010-05-07 2011-11-10 Boehringer Ingelheim International Gmbh Pyridazinones as gpr119 agonists
JP2013530947A (ja) 2010-05-17 2013-08-01 アレイ バイオファーマ、インコーポレイテッド Ｇｐｒ１１９調節薬としてのピペリジニル置換ラクタム
WO2011145718A1 (ja) 2010-05-21 2011-11-24 田辺三菱製薬株式会社 新規ピロロ［２，３－ｄ］ピリミジン化合物
TW201202230A (en) 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US20110293753A1 (en) 2010-05-28 2011-12-01 Louis Bellafiore Tocotrienol Compositions
WO2011151436A2 (en) 2010-06-04 2011-12-08 Euroscreen S.A. Novel compounds, method for use them and pharmaceutical composition containing them
GB201009873D0 (en) 2010-06-14 2010-07-21 Univ Leuven Kath Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
US20130096141A1 (en) 2010-06-18 2013-04-18 Bernard R. Neustadt Bicyclic heterocycle derivatives and methods of use thereof
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP2397039A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012006955A1 (en) 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. Compounds for treatment of metabolic disorders
KR20120011357A (ko) 2010-07-23 2012-02-08 현대약품 주식회사 치환된 피리디논 유도체 및 이의 제조방법
MA34474B1 (fr) 2010-07-23 2013-08-01 Connexios Life Sciences Pvt Ltd Agonistes de gpr40
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
KR20130099970A (ko) 2010-09-17 2013-09-06 어레이 바이오파마 인크. Gpr119 조절제로서의 피페리디닐-치환된 락탐류
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
CN102432598A (zh) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
SG188547A1 (en) 2010-10-08 2013-04-30 Cadila Healthcare Ltd Novel gpr 119 agonists
JP2014001144A (ja) 2010-10-08 2014-01-09 Nippon Chemiphar Co Ltd Ｇｐｒ１１９作動薬
CN101978956B (zh) * 2010-10-13 2012-03-28 北京京丰制药有限公司 盐酸二甲双胍肠溶片及其制备方法
CA2853974C (en) 2010-10-30 2020-11-10 Kindex Therapeutics, Llc Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
EP2643310A1 (en) 2010-11-23 2013-10-02 Pfizer Inc 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators
EP2643311A1 (en) 2010-11-26 2013-10-02 Lupin Limited Bicyclic gpr119 modulators
EP2646425B1 (en) 2010-12-01 2015-06-10 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
WO2012077655A1 (ja) 2010-12-07 2012-06-14 塩野義製薬株式会社 Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
CN103328482A (zh) 2011-01-03 2013-09-25 韩美药品株式会社 用于调节g蛋白-偶联受体的新双环化合物
WO2012098217A1 (en) 2011-01-21 2012-07-26 Boehringer Ingelheim International Gmbh Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders
CN102617548A (zh) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
TW201309639A (zh) 2011-02-17 2013-03-01 Lg Life Sciences Ltd 作為ｇｐｒ１１９促效劑之肟衍生物
WO2012123449A1 (en) 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9499467B2 (en) 2011-04-08 2016-11-22 Caldan Therapeutics Limited Ortho-fluoro substituted compounds for the treatment of metabolic diseases
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
BR112013027883A2 (pt) 2011-04-27 2017-08-08 Mochida Pharm Co Ltd novo derivado de 1-óxido de 3-hidroxiisotiazol
WO2012147516A1 (ja) 2011-04-28 2012-11-01 持田製薬株式会社 環状アミド誘導体
KR101401496B1 (ko) 2011-05-12 2014-06-11 한국화학연구원 티에노피리미딘 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 예방 또는 치료용 약학적 조성물
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2718288B1 (en) 2011-06-09 2015-03-11 Boehringer Ingelheim International GmbH Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders
JP2014159376A (ja) 2011-06-17 2014-09-04 Taisho Pharmaceutical Co Ltd アザスピロアルカン化合物
WO2013011402A1 (en) 2011-07-15 2013-01-24 Pfizer Inc. Gpr 119 modulators
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102357088A (zh) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 盐酸二甲双胍肠溶片

Also Published As

Publication number Publication date
CN104780915A (zh) 2015-07-15
AU2013290100A1 (en) 2015-01-29
IL236647A0 (en) 2015-02-26
CA2878625A1 (en) 2014-01-16
WO2014011926A1 (en) 2014-01-16
JP2018087214A (ja) 2018-06-07
JP2015522080A (ja) 2015-08-03
HK1210825A1 (en) 2016-05-06
EP2872127A1 (en) 2015-05-20

Similar Documents

Publication Publication Date Title
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
GT201200276A (es) Combinaciones de compuestos activos
CL2014000601A1 (es) Composición tópica veterinaria que comprende al menos un agente activo derivado de isoxazolina; y uso de la composición para el tratamiento o prevención de una infestación o infección por parásitos en un animal.
CL2014002087A1 (es) Composición veterinaria masticable que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal.
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
BR112012023021A2 (pt) compostos de indazol e seus usos
CU24336B1 (es) Compuestos de imidazopirrolidinona
CL2015001389A1 (es) Composiciones y compuestos antihelmínticos y métodos para usarlos.
DOP2016000253A (es) Nuevos compuestos
UY33598A (es) Imidazopiridazinas sustituidas
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
DOP2016000007A (es) Pirazolpiridinas sustituidas
NI201500118A (es) Imidazopiridazinas sustituidas
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2017001239A1 (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos. (divisional solicitud 2831-2014)
CO6551731A2 (es) Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica
CL2016000300A1 (es) Métodos terapéuticos
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
MX2017007856A (es) Composicion para el cuidado bucal.

Legal Events

Date Code Title Description
FB Suspension of granting procedure